» Articles » PMID: 37240189

The Spectrum of Neurological and Sensory Abnormalities in Gaucher Disease Patients: A Multidisciplinary Study (SENOPRO)

Abstract

Gaucher disease (GD) has been increasingly recognized as a continuum of phenotypes with variable neurological and sensory involvement. No study has yet specifically explored the spectrum of neuropsychiatric and sensory abnormalities in GD patients through a multidisciplinary approach. Abnormalities involving the nervous system, including sensory abnormalities, cognitive disturbances, and psychiatric comorbidities, have been identified in GD1 and GD3 patients. In this prospective study, named SENOPRO, we performed neurological, neuroradiological, neuropsychological, ophthalmological, and hearing assessments in 22 GD patients: 19 GD1 and 3 GD3. First, we highlighted a high rate of parkinsonian motor and non-motor symptoms (including high rates of excessive daytime sleepiness), especially in GD1 patients harboring severe glucocerebrosidase variants. Secondly, neuropsychological evaluations revealed a high prevalence of cognitive impairment and psychiatric disturbances, both in patients initially classified as GD1 and GD3. Thirdly, hippocampal brain volume reduction was associated with impaired short- and long-term performance in an episodic memory test. Fourthly, audiometric assessment showed an impaired speech perception in noise in the majority of patients, indicative of an impaired central processing of hearing, associated with high rates of slight hearing loss both in GD1 and GD3 patients. Finally, relevant structural and functional abnormalities along the visual system were found both in GD1 and GD3 patients by means of visual evoked potentials and optical coherence tomography. Overall, our findings support the concept of GD as a spectrum of disease subtypes, and support the importance of in-depth periodic monitoring of cognitive and motor performances, mood, sleep patterns, and sensory abnormalities in all patients with GD, independently from the patient's initial classification.

Citing Articles

Fucosidosis: A Review of a Rare Disease.

Pekdemir B, Bechelany M, Karav S Int J Mol Sci. 2025; 26(1.

PMID: 39796208 PMC: 11719934. DOI: 10.3390/ijms26010353.


Gaucher Disease Coexisting with Cytomegalovirus Infection: A Rare Presentation in an Infant.

Zhang Z, Liu D, Yu Z, Xiao Z, Zhou K, Li B Am J Case Rep. 2024; 25:e943398.

PMID: 38509666 PMC: 10964954. DOI: 10.12659/AJCR.943398.


A review of type 3 Gaucher disease: unique neurological manifestations and advances in treatment.

Zhong W, Li D, Fei Y, Hong P Acta Neurol Belg. 2024; 124(4):1213-1223.

PMID: 38413480 DOI: 10.1007/s13760-024-02493-1.


Examining the Role of a Functional Deficiency of Iron in Lysosomal Storage Disorders with Translational Relevance to Alzheimer's Disease.

Levine S Cells. 2023; 12(22).

PMID: 37998376 PMC: 10670892. DOI: 10.3390/cells12222641.

References
1.
Bamiou D, Campbell P, Liasis A, Page J, Sirimanna T, Boyd S . Audiometric abnormalities in children with Gaucher disease type 3. Neuropediatrics. 2001; 32(3):136-41. DOI: 10.1055/s-2001-16611. View

2.
Riboldi G, Di Fonzo A . , Gaucher Disease, and Parkinson's Disease: From Genetic to Clinic to New Therapeutic Approaches. Cells. 2019; 8(4). PMC: 6523296. DOI: 10.3390/cells8040364. View

3.
Postuma R, Arnulf I, Hogl B, Iranzo A, Miyamoto T, Dauvilliers Y . A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. Mov Disord. 2012; 27(7):913-6. PMC: 4043389. DOI: 10.1002/mds.25037. View

4.
El-Morsy Z, Khashaba M, Soliman O, Yahia S, El-Hady D . Glucosidase acid beta gene mutations in Egyptian children with Gaucher disease and relation to disease phenotypes. World J Pediatr. 2011; 7(4):326-30. DOI: 10.1007/s12519-011-0309-1. View

5.
Grasby P, Frith C, Friston K, Bench C, Frackowiak R, Dolan R . Functional mapping of brain areas implicated in auditory--verbal memory function. Brain. 1993; 116 ( Pt 1):1-20. DOI: 10.1093/brain/116.1.1. View